Survival of patients treated with radiation therapy for anaplastic astrocytoma

  • Christopher Barker Memorial Sloan-Kettering Cancer Center
  • Maria Chang Memorial Sloan-Kettering Cancer Center
  • Kathryn Beal Memorial Sloan-Kettering Cancer Center
  • Timothy A. Chan Memorial Sloan-Kettering Cancer Center

Abstract

Background. Anaplastic astrocytoma (AA) represents 7% of primary brain tumors in adults. Patient-, tumor-, and treatment-related factors are thought to be predictive of survival.  We retrospectively assessed the association of patient-, tumor-, and treatment-related factors with survival in AA treated with radiotherapy (RT) at our institution.

Methods. Medical records of patients with AA treated with RT between 1987 and 2007 were reviewed. Patient-, tumor-, and treatment-related variables were recorded and used to assign patients to a Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA) classification. First use of chemotherapy was recorded. Log-rank tests and Cox regression models were used to assess for an association of patient-, tumor- and treatment-related factors with survival.

Results. One-hundred twenty-six patients were eligible for study. Median age, Karnofsky performance status, and duration of symptoms were 43 years, 90, and 8 weeks. Median radiation dose was 59.4 Gy; 61% of patients underwent tumor resection, and 17% and 41% of patients received temozolomide during and after RT.  Median survival was 31 months, and 2-year survival was 58%. RTOG RPA class was associated with survival (p < 0.001), but use of temozolomide during or after RT was not (p > 0.05).


Conclusions. In this retrospective study with inherent limitations, RTOG RPA classification was associated with survival. Further studies are necessary to confirm or refute this finding.

Published
2014-10-26
How to Cite
Barker, C., Chang, M., Beal, K., & Chan, T. A. (2014). Survival of patients treated with radiation therapy for anaplastic astrocytoma. Radiology and Oncology, 48(4). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/2101
Section
Clinical oncology